Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The islet amyloid polypeptide (amylin or diabetes associated peptide or insulinoma amyloid peptide or IAPP) targeted pipeline therapeutics report provides comprehensive information on the islet amyloid polypeptide targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in islet amyloid polypeptide targeted therapeutics development with respective active and dormant or discontinued projects.
What are the key mechanism of actions in the islet amyloid polypeptide targeted pipeline therapeutics market?
The key mechanism of actions in the islet amyloid polypeptide targeted pipeline therapeutics market are islet amyloid polypeptide activator and islet amyloid polypeptide inhibitor.
Islet amyloid polypeptide targeted pipeline therapeutics market, by MoA
For more MoA insights, download a free sample
What are the key route of administration in the islet amyloid polypeptide targeted pipeline therapeutics market?
The key route of administration in the islet amyloid polypeptide targeted pipeline therapeutics market are subcutaneous, intravenous and oral.
key route of administration in the islet amyloid polypeptide targeted pipeline therapeutics
For more RoA insights, download a free sample
What are the key molecule type in the islet amyloid polypeptide targeted pipeline therapeutics market?
The key molecule type in the islet amyloid polypeptide targeted pipeline therapeutics market are synthetic peptide, recombinant peptide, small molecule, monoclonal antibody, and peptide.
key molecule type in the islet amyloid polypeptide targeted pipeline therapeutics market
For more molecule type insights, download a free sample
What are the key companies in the islet amyloid polypeptide targeted pipeline therapeutics market?
The key companies in the islet amyloid polypeptide targeted pipeline therapeutics market are ADM Therapeutics, Adocia SAS, Eli Lilly and Co, Gubra ApS, Intarcia Therapeutics Inc, Neurimmune Holding AG, Nordic Bioscience AS, ProMIS Neurosciences Inc, reMYND NV, Wren Therapeutics Ltd, and Zealand Pharma AS.
key companies in the islet amyloid polypeptide targeted pipeline therapeutics market
To know about more key companies, download a free sample
Market report overview
Key route of administration | Subcutaneous, Intravenous and Oral |
Islet Amyloid Polypeptide Activator and Islet Amyloid Polypeptide Inhibitor | |
Key molecule type | Synthetic Peptide, Recombinant Peptide, Small Molecule, Monoclonal Antibody, and Peptide |
Key companies | ADM Therapeutics, Adocia SAS, Eli Lilly and Co, Gubra ApS, Intarcia Therapeutics Inc, Neurimmune Holding AG, Nordic Bioscience AS, ProMIS Neurosciences Inc, reMYND NV, Wren Therapeutics Ltd, and Zealand Pharma AS |
Scope
- The report provides a snapshot of the global therapeutic landscape for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)
- The report reviews Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Adocia SAS
Eli Lilly and Co
Gubra ApS
Intarcia Therapeutics Inc
Neurimmune Holding AG
Nordic Bioscience AS
ProMIS Neurosciences Inc
reMYND NV
Wren Therapeutics Ltd
Zealand Pharma AS
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key mechanism of actions in the islet amyloid polypeptide targeted pipeline therapeutics market?
Islet amyloid polypeptide activator and islet amyloid polypeptide inhibitor are the key mechanism of actions in the islet amyloid polypeptide targeted pipeline therapeutics market.
-
What are the key route of administration in the islet amyloid polypeptide targeted pipeline therapeutics market?
Subcutaneous, intravenous and oral are the key route of administration in the islet amyloid polypeptide targeted pipeline therapeutics market.
-
What are the key molecule type in the islet amyloid polypeptide targeted pipeline therapeutics market?
Synthetic peptide, recombinant peptide, small molecule, monoclonal antibody, and peptide are the key molecule type in the islet amyloid polypeptide targeted pipeline therapeutics market.
-
What are the key companies in the islet amyloid polypeptide targeted pipeline therapeutics market?
ADM Therapeutics, Adocia SAS, Eli Lilly and Co, Gubra ApS, Intarcia Therapeutics Inc, Neurimmune Holding AG, Nordic Bioscience AS, ProMIS Neurosciences Inc, reMYND NV, Wren Therapeutics Ltd, and Zealand Pharma AS are the key companies in the islet amyloid polypeptide targeted pipeline therapeutics market.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.